Early trial tests 'Engineered' transplant to fight leukemia without lifelong drugs
NCT ID NCT04678401
Summary
This early-stage study is testing a new type of stem cell transplant for adults with aggressive or hard-to-treat forms of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if adding special donor immune cells can help the transplant fight the cancer while reducing the risk of a dangerous complication where the donor cells attack the patient's body. About 30 participants will receive the experimental transplant and be followed for one year to check safety and early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.